|Titre :||A randomized trial of e-cigarettes versus nicotine-replacement therapy (2019)|
|Auteurs :||P. HAJEK ; A. PHILLIPS-WALLER ; D. PRZULJ ; F. PESOLA ; K. MYERS SMITH ; N. BISAL ; J. LI ; S. PARROTT ; P. SASIENI ; L. DAWKINS ; L. ROSS ; M. GONIEWICZ ; Q. WU ; H. J. MCROBBIE|
|Type de document :||Article : Périodique|
|Dans :||New England Journal of Medicine (Online first 30/01/2019)|
|Article en page(s) :||9 p., doi: 10.1056/NEJMoa1808779|
|Discipline :||TRA (Traitement et prise en charge / Treatment and care)|
Thésaurus TOXIBASECIGARETTE ELECTRONIQUE ; SUBSTITUTS NICOTINIQUES ; ETUDE RANDOMISEE ; COMPARAISON ; SEVRAGE ; EFFICACITE ; ABSTINENCE
Background: E-cigarettes are commonly used in attempts to stop smoking, but evidence is limited regarding their effectiveness as compared with that of nicotine products approved as smoking-cessation treatments.
Methods: We randomly assigned adults attending U.K. National Health Service stop-smoking services to either nicotine-replacement products of their choice, including product combinations, provided for up to 3 months, or an e-cigarette starter pack (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg per milliliter]), with a recommendation to purchase further e-liquids of the flavor and strength of their choice. Treatment included weekly behavioral support for at least 4 weeks. The primary outcome was sustained abstinence for 1 year, which was validated biochemically at the final visit. Participants who were lost to follow-up or did not provide biochemical validation were considered to not be abstinent. Secondary outcomes included participant-reported treatment usage and respiratory symptoms.
Results: A total of 886 participants underwent randomization. The 1-year abstinence rate was 18.0% in the e-cigarette group, as compared with 9.9% in the nicotine-replacement group (relative risk, 1.83; 95% confidence interval [CI], 1.30 to 2.58; P Conclusions: E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy, when both products were accompanied by behavioral support. (Funded by the National Institute for Health Research and Cancer Research UK; Current Controlled Trials number, ISRCTN60477608.)
|Domaine :||Tabac / Tobacco|
|Refs biblio. :||26|
|Affiliation :||Queen Mary University of London, King's College London, London South Bank University, London, UK|